Form 4 for JAZZ Jazz Pharmaceuticals plc
Accepted 2025-05-13 00:00:00 ET · period of report 2025-05-09 · accession 0001765581-25-000042 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-05-13 | 2025-05-09+ | JAZZ | Mulligan Seamus | Dir | P - Purchase | $98.33 | +101.6K | 99.9K | New | +$9.99M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-05-12 | P | A | 1,621 | $103.00 | 101,621 | I By Nerano Pharma Lim | — | — | (F4) Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $102.97 to $103.00. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. (F2) Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. |
| 2 | Common | Ordinary Shares | 2025-05-09 | P | A | 100 | $99.71 | 100,000 | I By Nerano Pharma Lim | — | — | (F2) Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. |
| 3 | Common | Ordinary Shares | 2025-05-09 | P | A | 80,684 | $98.10 | 80,684 | I By Nerano Pharma Lim | — | — | (F1) Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $97.56 to $98.5542. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. (F2) Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. |
| 4 | Common | Ordinary Shares | 2025-05-09 | P | A | 19,216 | $98.91 | 99,900 | I By Nerano Pharma Lim | — | — | (F3) Reflects the purchase of ordinary shares executed in multiple transactions at prices ranging from $98.56 to $99.47. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected. (F2) Shares beneficially owned by Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. |